TNFSF11 and breast carcinoma: Next, we searched the TCGA database and found that the rate of mutation of RANKL was less than 2% in all enrolled endometrial cancer cases (Supplementary Fig. 2A, B) and its mutation rate was not profiled in breast carcinoma (Supplementary Fig. 2C).